GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (MEX:OGN) » Definitions » Capital Expenditure

Organon (MEX:OGN) Capital Expenditure : MXN-7,094.91 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Organon Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Organon's cash flow for capital expenditures for the three months ended in Mar. 2025 was MXN-1,984 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-7,094.91 Mil.

Organon Capital Expenditure Historical Data

The historical data trend for Organon's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Capital Expenditure Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -5,072.46 -10,010.83 -8,324.79 -4,430.28 -7,320.35

Organon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,593.24 -861.05 -1,496.46 -2,752.95 -1,984.45

Organon Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7,094.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (MEX:OGN) » Definitions » Capital Expenditure
Comparable Companies
AMRN MDCX SCLX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
OGN:USA 1OGN:Italy 0A9W:UK 7XP:Germany
Address
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Website
https://www.organon.com
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.